Click here for slides on this topic


JUPITER Study

Abbreviation for the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin study.
The following content matched the glossary term: JUPITER Study

Clinical Insights in Diabetes Newsletter November 2012

Top

Clinical Insights® in Diabetes Newsletter November 2012.

Statins and diabetes, Roux-en-Y for type 2 diabetes and obesity, sitagliptin or liraglutide for type 2 diabetes treatment, obesity and mortality, and DPP-4 inhibitors and cardiovascular disease.

Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project

Top

Rautio N, Jokelainen J, Oksa H, et al. Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. BMJ Open. 2012;2(5). pii: e001472. doi: 10.1136/bmjopen-2012-001472. Treatment with statins has been linked to an increased risk for type 2 diabetes in several post-hoc evaluations of previous completed trials, leading to controversy regarding the risk/benefit profile of statin therapy for primary prevention in patients who are at low risk for developing cardiovascular (CV) events.

Press Room

Top

NDEI.org press releases and news.

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

Top

Sattar N, Preiss D, Murrary HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742. Sattar and colleagues conducted a meta-analysis to assess whether a relationship between statin use and development of diabetes exists.

NDEI.org Expert Commentary on the JUPITER trial Peter Libby

Top

Peter Libby, MD, provides expert commentary on a new analysis from the JUPITER trial examining whether the benefits of statin use outweigh diabetes risk in primary prevention low-risk patients

JUPITER: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-reactive Protein

Top

Ridker PM, Danielson E, Fonseca FA, et al; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. The Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) was a randomized, double-blind, placebo-controlled trial which sought to examine whether rosuvastatin treatment compared with placebo would decrease the rate of first cardiovascular (CV) events.

JUPITER Analysis: Do Statin Benefits Outweigh Diabetes Risk?

Top

Exclusive! Expert commentary from Peter Libby, MD, on this analysis of the JUPITER trial. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565-571.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 11, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 11, 2012

ORIGIN trial results, insulin and cancer, TINSAL-T2D results, and more.

NDEI.org Expert Commentary Statins and Gender Peter Ganz

Top

Expert commentary on statins and gender from Peter Ganz, MD.

Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER

Top

Michos ED, Blumenthal RS. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the US. J Am Coll Cardiol. 2009;53(11):931-935. We assessed the prevalence of low-density lipoprotein-cholesterol (LDL-C) <130 mg/dl with elevated high-sensitivity C-reactive protein (hsCRP) in the National Health And Nutrition Examination Survey (NHANES), weighted to be representative of the general U.S. population.



Slide Library Results

Search Results for: JUPITER Study Slides Found: 23
JUPITER: Design
JUPITER Analysis: Do Statin Benefits Outweigh Diabetes Risk?
JUPITER Analysis: Design
JUPITER Analysis: Baseline Characteristics 0 or ≥1 Major Diabetes Risk Factor*
JUPITER Analysis: Increased Diabetes Risk With ≥1 Risk Factor* at Baseline
JUPITER Analysis: Incident Diabetes by Treatment Group
JUPITER Analysis: Average Time to Diabetes Diagnosis
JUPITER Analysis: Risk Reduction With Rosuvastatin ≥1 Major Diabetes Risk Factor*
JUPITER Analysis: Risk Reduction With Rosuvastatin No Major Diabetes Risk Factor*
JUPITER Analysis: CV Risk Reduction Among Subjects Who Developed Diabetes
JUPITER Analysis: Conclusions
JUPITER: Study Design
JUPITER: Lipid and HsCRP Levels
JUPITER Results: Primary Endpoint
JUPITER Results: Components of Primary Endpoint
JUPITER Results: Summary
JUPITER Analysis: Limitations
JUPITER Secondary Analysis Assesses Statin Use & Diabetes Risk | NDEI
JUPITER High-Intensity Rosuvastatin & Lipoprotein Particles | NDEI
JUPITER Effect of High-Intensity Rosuvastatin on Lipoproteins Diabetes | NDEI
JUPITER Rosuvastatin & Incident Type 2 Diabetes | NDEI
JUPITER Insulin Resistance Associated With Risk Factors | NDEI
JUPITER Incident Diabetes Associated With More Risk Factors Rosuvastatin | NDEI